In this episode, we explore radiotherapy biotech with Mats Hansen. He is the CEO of Spago Nanomedical AB, a biotech firm advancing cancer treatment with new radiopharmaceuticals.
Mats discusses the challenges and opportunities in the radiopharmaceutical space and provides insights into nanomedical radiopharmaceuticals for cancer treatment using lutetium-177.
He also shares his experiences and insights on leadership and communication skills, emphasizing the importance of effective communication in leadership roles, and discusses how his approach to leadership has evolved over the years.
Here's what you are in for:
00:00 Introduction
05:08 - Experience in Drug Development
13:19 - The Role of AI on Pharma and BioTech
15:19 - Spargo Nanomedical and Recent Developments
23:15- Challenges and Opportunities in Radiopharmaceutical Space
25:48 - Considerations for Investors
31:19 - Challenges and Growth as a CEO
ABOUT MATS
Mats Hansen, a scientist from southern Sweden, loves nature deeply and is curious and passionate about science. These driving forces propelled him to pursue a career in science and pharmaceutical development. Mats has come a long way, from his start in plant breeding and working with molecular markers to now being the CEO of Spago Nanomedical AB. By applying scientific knowledge in an industrial setting, he has adeptly navigated the challenges of drug development, continuously refining his skills in communication and leadership along the way.
Connect with Mats on:
ABOUT CHARLES
Charles Spence leads Discera, a leading recruitment firm specializing in the biopharma industry. He graduated with a biomedical degree, has worked in hospitals (including translation work in Seoul, South Korea) and also spent years doing research in diabetes. After doing research and travel, a career in business and science felt the most appropriate.
In 2023, Charles decided to launch his firm - Discera Search. A firm committed to solving the biggest talent needs of Early clinical stage SME biotechs on the East Coast and DACH.
Connect with Charles:
